Picture loading failed.

Anti-C5 therapeutic antibody (Pre-made Eculizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Eculizumab, sold under the brand name Soliris among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. In people with PNH, it reduces both the destruction of red blood cells and need for blood transfusion, but does not appear to affect the risk of death. Eculizumab was the first drug approved for each of its uses, and its approval was granted based on small trials.[2][3][4][5] It is given in a clinic by intravenous (IV) infusion.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-164-1mg 1mg 3090
GMP-Bios-ab-164-10mg 10mg 21890
GMP-Bios-ab-164-100mg 100mg 148000
GMP-Bios-ab-164-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-C5 therapeutic antibody (Pre-made Eculizumab biosimilar,Whole mAb)
INN Name Eculizumab
TargetC5
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5i5k:HL:XY
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2002
Year Recommended2003
CompaniesAlexion Pharmaceuticals;Brigham and Womens Hospital;Chiba University;Handok Inc
Conditions ApprovedNeuromyelitis optica;Haemolytic uraemic syndrome;Myasthenia gravis;Paroxysmal nocturnal haemoglobinuria
Conditions ActiveDelayed graft function;Guillain-Barre syndrome;Renal transplant rejection;COVID-19
Conditions DiscontinuedAntiphospholipid syndrome;Heart transplant rejection;Adult respiratory distress syndrome;Age-related macular degeneration;Allergic asthma;Autoimmune haemolytic anaemia;Bullous pemphigoid;Dermatomyositis;Glomerulonephritis;Idiopathic thrombocytopenic purpura;Lupus nephritis;Membranous glomerulonephritis;Motor neuron disease;Psoriasis;Rheumatoid arthritis;Systemic lupus erythematosus
Development TechGS Gene Expression System